title: Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial.
abstract: OBJECTIVE
  The aim of the current study was to test the influence of topiramate on behavior, body weight, and health-related quality of life (HRQOL) in bulimic patients.
  
  
  METHODS
  Thirty patients with bulimia nervosa were treated with topiramate in a 10-week randomized, double-blind, placebo-controlled study. The subjects were randomly assigned to receive topiramate (topiramate group [TG]; n = 30) or a placebo (control group [CG]; n = 30). Primary outcome measures were changes in the frequency of binging/purging, in body weight, and on the SF-36 Health Survey (SF-36) scales.
  
  
  RESULTS
  In comparison to the CG group (according to the intent-to-treat principle), significant changes in the frequency of binging/purging (a > 50% reduction: TG, n = 11 [36.7%]; CG, n = 1 [3.3%]; p < .001), body weight (difference in weight loss between the two groups: 3.8 kg, 95% confidence interval [CI] = -5.4 to -2.1; p < .001), and SF-36 (all ps < .001) could be seen. All patients tolerated topiramate well.
  
  
  CONCLUSIONS
  Topiramate appears to safe and effective in influencing the frequency of binging/purging, body weight, and HRQOL in bulimic patients.
authors.affiliation: Clinic for Psychosomatic Medicine, Inntalklinik, Simbach am Inn, Germany. m.nickel@inntalklinik.de
authors.forename: Cerstin
authors.initials: C
authors.lastname: Nickel
authors.forename: Karin
authors.initials: K
authors.lastname: Tritt
authors.forename: Moritz
authors.initials: M
authors.lastname: Muehlbacher
authors.forename: Francisco
authors.initials: F
authors.lastname: Pedrosa Gil
authors.forename: Ferdinand O
authors.initials: FO
authors.lastname: Mitterlehner
authors.forename: Patrick
authors.initials: P
authors.lastname: Kaplan
authors.forename: Claas
authors.initials: C
authors.lastname: Lahmann
authors.forename: Peter K
authors.initials: PK
authors.lastname: Leiberich
authors.forename: Jakub
authors.initials: J
authors.lastname: Krawczyk
authors.forename: Christian
authors.initials: C
authors.lastname: Kettler
authors.forename: Wolfhardt K
authors.initials: WK
authors.lastname: Rother
authors.forename: Thomas H
authors.initials: TH
authors.lastname: Loew
authors.forename: Marius K
authors.initials: MK
authors.lastname: Nickel
mesh_terms: D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D001294:Attitude to Health; D002032:Bulimia / Q000188:drug therapy*; D015897:Comorbidity; D004311:Double-Blind Method; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015438:Health Behavior; D006801:Humans; D010552:Personality Assessment / Q000706:statistics & numerical data; D011594:Psychometrics; D000077236:Topiramate; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose